The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2018

Filed:

Jul. 27, 2009
Applicants:

Michael Donovan, Cambridge, MA (US);

Faisal Khan, Fishkill, NY (US);

Gerardo Fernandez, Yorktown Heights, NY (US);

Ali Tabesh, Montvale, NJ (US);

Ricardo Mesa-tejada, Pleasantville, NY (US);

Carlos Cordon-cardo, New York, NY (US);

Jose Costa, Guilford, CT (US);

Stephen Fogarasi, Pawling, NY (US);

Yevgen Vengrenyuk, Mamaroneck, NY (US);

Inventors:

Michael Donovan, Cambridge, MA (US);

Faisal Khan, Fishkill, NY (US);

Gerardo Fernandez, Yorktown Heights, NY (US);

Ali Tabesh, Montvale, NJ (US);

Ricardo Mesa-Tejada, Pleasantville, NY (US);

Carlos Cordon-Cardo, New York, NY (US);

Jose Costa, Guilford, CT (US);

Stephen Fogarasi, Pawling, NY (US);

Yevgen Vengrenyuk, Mamaroneck, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G06G 7/48 (2006.01); G06F 19/00 (2011.01);
U.S. Cl.
CPC ...
G06F 19/3437 (2013.01); G06F 19/345 (2013.01); G06F 19/3443 (2013.01);
Abstract

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.


Find Patent Forward Citations

Loading…